96. クローン病 Crohn disease Clinical trials / Disease details

臨床試験数 : 2,442 / 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2006-002027-16-GR (EUCTR)	12/12/2006	05/09/2006	Certolizumab pegol 400 mg monthly in the treatment of adult Greek patients with moderate to severe Crohn’s Disease, who have been previously treated successfully with infliximab but who have subsequently lost the response or have developed intolerance to infliximab: an open-label, multi-center, single-cohort study to evaluate efficacy, safety and onset of action.	Certolizumab pegol 400 mg monthly in the treatment of adult Greek patients with moderate to severe Crohn’s Disease, who have been previously treated successfully with infliximab but who have subsequently lost the response or have developed intolerance to infliximab: an open-label, multi-center, single-cohort study to evaluate efficacy, safety and onset of action.	Certolizumab pegol in the treatment of adult Greek patients with moderate to severe Crohn’s Disease, who have been previously treated successfully with infliximab but who have subsequently lost the response or have developed intolerance to infliximab	Product Name: certolizumab pegol Product Code: CDP870	UCB AE	NULL	Not Recruiting			Female: yes Male: yes	50	Phase 3	Greece
2	NCT00349752 (ClinicalTrials.gov)	November 2006	30/6/2006	Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease	A Phase IIIb Multicenter, Double-blind, Placebo-controlled,Randomized Trial to Examine the Corticosteroid-sparing Effect of Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease.	Crohn's Disease	Biological: certolizumab pegol 400 mg;Other: Placebo	UCB Pharma	NULL	Terminated	18 Years	N/A	All	174	Phase 3	United States;Canada;Germany;Belgium